Financial statements of

Sinai Health System

March 31, 2016

Sinai Health System For the year ended March 31, 2016

Table of contents

Independent auditor's report	1-2
Statement of financial position	3
Statement of operations	4
Statement of changes in net assets	5
Statement of remeasurement gains and losses	6
Statement of cash flows	7
Notes to the financial statements	8-23



June 14, 2016

Independent Auditor's Report

To the Board of Directors of Sinai Health System

We have audited the accompanying financial statements of Sinai Health System, which comprise the statements of financial position as at March 31, 2016 and the statements of operations, statements of changes in net assets (deficit), remeasurement gains and losses and cash flows for the years then ended, and the related notes, which comprise a summary of significant accounting policies and other explanatory information.

Management's responsibility for the financial statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian public sector accounting standards, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the financial statements present fairly, in all material respects, the financial position of Sinai Health System as at March 31, 2016 and the results of its operations, its remeasurement gains and losses and its cash flows for the years then ended in accordance with Canadian public sector accounting standards.

Pricewaterhouse Coopers LLP

Chartered Professional Accountants, Licensed Public Accountants

Sinai Health System Statement of financial position

As at March 31, 2016 (in thousands of dollars)

	2016	2015
	\$	\$
Assets		
Current assets		
Cash (Note 3)	82,497	102,769
Restricted cash (Note 4)	11,861	11,064
Short-term investments (Note 5)	23,334	20,750
Accounts receivable (Notes 6 and 14)	40,429	38,086
Capital grants receivable (Note 7)	5,945	4,946
Inventories	3,236	3,335
Prepaid deposits and sundry assets (Notes 14 and 17)	4,411	3,647
	171,713	184,597
Restricted cash (Note 4)	4,272	9,473
Capital grants receivable (Note 7)	3,645	3,705
Due from related entities (Note 14)	4,771	4,796
Other long-term assets (Note 8)	9,626	4,144
Property and equipment (Note 9)	1,075,814	1,090,879
	1,269,841	1,297,594
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities (Note 17)	84,518	92,162
Administered funds	10,799	10,603
Current portion of long-term liabilities (Note 10)	1,189	1,482
Current portion of long-term redevelopment obligation (Note 11)	6,743	6,415
Deferred contributions (Note 13)	70,165	76,048
	173,414	186,710
Long-term liabilities (Note 10)	106,168	103,787
Long-term redevelopment obligation (Note 11)	368,438	374,412
Employee future benefits (Note 12)	25,910	24,534
Deferred contributions (Note 13)	593,945	600,600
	1,267,875	1,290,043
Net assets consist of		
Unrestricted	5,216	10,129
Accumulated remeasurement losses	(3,250)	(2,578)
. 100 S. I. S.	1,966	7,551
	1,269,841	1,297,594

Director

Director

Commitments and contingencies (Note 17)

See accompanying notes to financial statements.

Approved by the Board

Sinai Health System Statement of operations

For the year ended March 31, 2016 (in thousands of dollars)

	2016	2015
	\$	\$
Income		
Ministry of Health and Long-Term Care (MOHLTC)	424,922	430,498
Patient revenue	17,312	15,900
Preferred accommodation	11,586	11,392
Research funding (Note 15)	77,437	78,735
Commercial	10,379	11,799
Other revenue and recoveries	41,113	44,071
Amortization of deferred contributions for equipment	8,867	7,487
	591,616	599,882
Expenses		
Salaries and wages	297,557	301,306
Employee benefits	71,116	71,163
General supplies and other	93,416	95,727
Medical and surgical supplies	21,685	21,446
Drugs	12,892	13,462
Research (Note 15)	77,437	78,735
Amortization of equipment	15,591	13,987
Interest	1,735	1,702
Interest	591,429	597,528
Excess of income over expenses before the undernoted	187	2,354
·		
Amortization of deferred capital contributions	39,564	37,778
Amortization of building and research equipment	(45,613)	(43,373
	(6,049)	(5,595
Funding of interest - building	20,185	20,495
Interest cost on building (MOHLTC share)	(20,185)	(20,495
	-	-
Deficiency of income over expenses for the year	(5,862)	(3,241

Sinai Health System Statement of changes in net assets

For the year ended March 31, 2016 (in thousands of dollars)

	Investment in		2016	2015
	capital assets	Unrestricted	Total	Total
	\$	\$	\$	\$
Balance, beginning of year	3,023	7,106	10,129	10,347
Deficiency of income over expenses for the year	-	(5,862)	(5,862)	(3,241)
Donated artwork (Note 9)	949	-	949	3,023
Balance, end of year	3,972	1,244	5,216	10,129

Statement of remeasurement gains and losses

For the year ended March 31, 2016 (in thousands of dollars)

	2016	2015
	\$	\$
Accumulated remeasurement gains (losses), beginning of year	(2,578)	803
Unrealized losses attributable to interest rate swaps (Note 10)	(672)	(3,381)
Accumulated remeasurement losses, end of year	(3,250)	(2,578)

Sinai Health System Statement of cash flows

For the year ended March 31, 2016 (in thousands of dollars)

Items not affecting cash		2016	2015
Operating activities Deficiency of income over expenses for the year (5,862) (3,241) Items not affecting cash 15,591 13,987 Amortization of building and research equipment 45,613 43,373 Re-evaluation of capital asset, building 1,430 45,613 Recognition of deferred capital contributions (48,892) (45,265) Recognition of deferred contributions (75,927) (81,348) Decrease (increase) in due from related entities 25 (250) Employee future benefits 2,656 2,246 Payment for employee tuture benefits (1,280) (491) Increase in other long-term assets (5,482) (634) Increase in other long-term sests (5,482) (634) Increase in other long-term liabilities 2,541 27,584 Decrease (increase) in capital grants receivable (939) 67 Net change in non-cash working capital (Note 16) (10,652) (6,331) Pinancing activities (1,125) (201) Repayment of long-term debt (1,125) (201) <t< td=""><td></td><td>\$</td><td>\$</td></t<>		\$	\$
Deficiency of income over expenses for the year Items not affecting cash	Cash provided by (used in)		
Items not affecting cash	Operating activities		
Amortization of equipment 15,591 13,987 Amortization of building and research equipment 45,613 43,373 Re-evaluation of capital asset, building 1,430 Recognition of deferred capital contributions (75,927) (81,348) Recognition of deferred contributions 25 (250) Berployee future benefits 2,666 2,246 Payment for employee future benefits (1,280) (491) Increase in other long-term assets (5,482) (634) Increase in other long-term liabilities 2,541 27,584 Decrease (increase) in capital grants receivable (939) 67 Net change in non-cash working capital (Note 16) (10,652) (6,931) Pinancing activities (1,125) (201) Repayment of long-term debt (1,125) (201) Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital asset of \$434 (2015 - \$nil) 31,929 49,060 Deferred contributions received 7,918 81,018	Deficiency of income over expenses for the year	(5,862)	(3,241)
Amortization of building and research equipment 45,613 43,373 Re-evaluation of capital asset, building 1,430 - Recognition of deferred capital contributions (75,927) (81,348) Recognition of deferred contributions (75,927) (81,348) Decrease (increase) in due from related entities 25 (250) Employee future benefits (1,280) (491) Increase in other long-term assets (5,482) (634) Increase in other long-term liabilities 2,541 27,584 Decrease (increase) in capital grants receivable (393) 67 Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) Repayment of long-term debt (1,125) (201) Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital asset of \$434 (2015 - \$nil) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness<	Items not affecting cash		
Re-evaluation of capital asset, building 1,430 - Recognition of deferred capital contributions (48,892) (45,265) (81,348) Decrease (increase) in due from related entities 25 (250) (250) Employee future benefits 2,666 (2,246) (491) Payment for employee future benefits (1,280) (491) (491) Increase in other long-term assets (5,482) (634) (634) Increase in other long-term liabilities 2,541 (27,584) 27,584 Decrease (increase) in capital grants receivable (939) (67) 67 Net change in non-cash working capital (Note 16) (10,652) (6,931) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) (6,903) Financing activities 8 (201) (6,415) (50,903) Financing activities (1,125) (201) (201) (6,103) (201) Repayment of long-term debt (1,125) (6,931) (6,103) (201) (6,103) (201) (6,103) (201) (6,103) (201) (6,103) (201) (201) (201) (201) (201) (201)	Amortization of equipment	15,591	13,987
Recognition of deferred capital contributions (48,892) (45,265) Recognition of deferred contributions (75,927) (81,348) Decrease (increase) in due from related entities 25 (250) Employee future benefits 2,656 2,246 Payment for employee future benefits (1,280) (491) Increase in other long-term assets (5,482) (634) Increase in other long-term liabilities 2,541 27,584 Decrease (increase) in capital grants receivable (939) 67 Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (1,125) (201) Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil) 31,929 49,060 Decrease in bank indebtedness - (3,23	Amortization of building and research equipment	45,613	43,373
Recognition of deferred contributions (75,927) (81,348) Decrease (increase) in due from related entities 25 (250) Employee future benefits 2,656 2,246 Payment for employee future benefits (1,280) (491) Increase in other long-term assets (5,482) (634) Increase in other long-term liabilities 2,541 27,584 Decrease (increase) in capital grants receivable (939) 67 Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) Pinancing activities (6,415) (6,103) Deferred contributions received (excluding donated capital asset of \$434 (2015 - \$nil) 31,929 49,060 Deferred contributions received 79,918 81,0	Re-evaluation of capital asset, building	1,430	-
Decrease (increase) in due from related entities	Recognition of deferred capital contributions	(48,892)	(45,265)
Employee future benefits 2,656 2,246 Payment for employee future benefits (1,280) (491) Increase in other long-term assets (5,482) (634) Increase in other long-term liabilities 2,541 27,584 Decrease (increase) in capital grants receivable (939) 67 Net change in non-cash working capital (Note 16) (10,652) (6,931) Net change in non-cash working capital (Note 16) (10,652) (6,931) Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Toxesting activities - - Purchase of investments (5,160) (4,285) Proceeds on redemption of investments (5,160) 3,230 Capital activities - -	Recognition of deferred contributions	(75,927)	(81,348)
Payment for employee future benefits (1,280) (491) Increase in other long-term assets (5,482) (634) Increase in other long-term liabilities 2,541 27,584 Decrease (increase) in capital grants receivable (939) 67 (70,526) (43,972) Net change in non-cash working capital (Note 16) (10,652) (6,931) Financing activities (81,178) (50,903) Feapayment of long-term debt (1,125) (201) Repayment of long-term debt (excluding donated capital asset of \$434 (2015 - \$nill) 31,929 49,060 Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nill) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Total process of investments (5,160) (4,285) Purchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments (2,504) 3,936 <td>Decrease (increase) in due from related entities</td> <td>25</td> <td>(250)</td>	Decrease (increase) in due from related entities	25	(250)
Increase in other long-term assets (5,482) (634) Increase in other long-term liabilities 2,541 27,584 Decrease (increase) in capital grants receivable (939) 67 Repayment of long-term debt (10,652) (6,931) (81,178) (50,903) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital asset of \$434 (2015 - \$nil) 31,929 49,060 Deferred contributions received (excluding donated capital asset of \$434 (2015 - \$nil) 31,929 49,060 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Decrease in restricted cash 4,600 7,413 Investing activities (5,160) (4,285) Purchase of investments (5,160) (4,285) Sale of investments 2,500 (8,221) Capital activities (45,501) (58,236) Capital activities (45,501) (58,236) Loss on capital asset write-off 84	Employee future benefits	2,656	2,246
Increase in other long-term liabilities 2,541 27,584 Decrease (increase) in capital grants receivable (939) 67 (70,526) (43,972) Net change in non-cash working capital (Note 16) (10,652) (6,931) (81,178) (50,903) Financing activities (1,125) (201) Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness 3,230 Decrease in restricted cash 4,600 7,413 Decrease in restricted cash 4,600 7,413 Tokapor 127,957 Investing activities (5,160) (4,285) Purchase of investments (5,160) (4,285) Sale of investments 2,500 8,221 Sale of investments 2,500 8,221 Capital activities (45,501) (58,236) Loss on capital asset write-off 84 - (45,501) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year (20,272)	Payment for employee future benefits	(1,280)	(491)
Decrease (increase) in capital grants receivable	Increase in other long-term assets	(5,482)	(634)
Net change in non-cash working capital (Note 16)	Increase in other long-term liabilities	2,541	27,584
Net change in non-cash working capital (Note 16) (10,652) (6,931) Financing activities Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil)) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Investing activities Varchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - - Sale of investments 2,500 8,221 - Sale of investments 2,500 8,221 Capital activities Varchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 90,015	Decrease (increase) in capital grants receivable	(939)	67
Financing activities (81,178) (50,903) Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil)) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 To sport the serior of investments (5,160) (4,285) Purchase of investments 76 - Sale of investments 2,500 8,221 Sale of investments 2,500 8,221 Capital activities 2,500 8,221 Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015		(70,526)	(43,972)
Financing activities (81,178) (50,903) Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil)) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 To sport the serior of investments (5,160) (4,285) Purchase of investments 76 - Sale of investments 2,500 8,221 Sale of investments 2,500 8,221 Capital activities 2,500 8,221 Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	Net change in non-cash working capital (Note 16)	(10,652)	(6,931)
Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil)) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Total activities 76 - Purchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Capital activities 2,500 8,221 Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	3 1 ()	'	(50,903)
Repayment of long-term debt (1,125) (201) Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil)) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Total activities 76 - Purchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Capital activities 2,500 8,221 Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015			
Repayment of long-term redevelopment obligation (6,415) (6,103) Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Investing activities Purchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Capital activities Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	<u> </u>	(4.40=)	(00.1)
Deferred capital contributions received (excluding donated capital asset of \$434 (2015 - \$nil) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Investing activities 108,907 127,957 Investing activities (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Sale of investments 2,500 8,221 Capital activities 2 (45,501) (58,236) Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	• •	, ,	, ,
donated capital asset of \$434 (2015 - \$nil) 31,929 49,060 Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 108,907 127,957 Investing activities Purchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Capital activities Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015		(6,415)	(6,103)
Deferred contributions received 79,918 81,018 Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Investing activities 108,907 127,957 Investing activities 5,160) (4,285) Purchase of investments 76 - Sale of investments 2,500 8,221 Capital activities (2,584) 3,936 Capital activities 84 - Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	, , , , ,		
Decrease in bank indebtedness - (3,230) Decrease in restricted cash 4,600 7,413 Investing activities 108,907 127,957 Investing activities 2,560 (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Capital activities (2,584) 3,936 Capital activities 84 - Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	· · · · · · · · · · · · · · · · · · ·		
Decrease in restricted cash 4,600 7,413 108,907 127,957 Investing activities Purchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Capital activities Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015		79,918	
Investing activities Purchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Capital activities (2,584) 3,936 Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015		-	
Investing activities Purchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Capital activities (2,584) 3,936 Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	Decrease in restricted cash		
Purchase of investments (5,160) (4,285) Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 Capital activities Urchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015		108,907	127,957
Proceeds on redemption of investments 76 - Sale of investments 2,500 8,221 (2,584) 3,936 Capital activities Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	-		
Sale of investments 2,500 8,221 Capital activities (2,584) 3,936 Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	Purchase of investments	(5,160)	(4,285)
Capital activities (2,584) 3,936 Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	·	76	-
Capital activities Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	Sale of investments	2,500	8,221
Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015		(2,584)	3,936
Purchase of property and equipment (45,501) (58,236) Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	Capital activities		
Loss on capital asset write-off 84 - (45,417) (58,236) Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015		(45.501)	(58 236)
Increase (decrease) in cash during the year (20,272) 22,754 Cash, beginning of year 102,769 80,015	, , , , , , , , , , , , , , , , , , , ,	· · ·	(00,200)
Cash, beginning of year 102,769 80,015	2000 on suprior decor mino on		(58,236)
Cash, beginning of year 102,769 80,015		(00.070)	00.754
		, , ,	
1.3cb obd 01.103k	Cash, end of year	82,497	102,769

Notes to the financial statements March 31, 2016 (In thousands of dollars)

1. Organization

Sinai Health System (the Hospital) is a public teaching and research hospital affiliated with the University of Toronto. The Hospital provides patient care, teaches healthcare professionals, conducts research and provides chronic care and rehabilitation services. The Hospital was formed as a result of the amalgamation of Mount Sinai Hospital (MSH) and Bridgepoint Hospital (BH) effective January 1, 2015.

The Hospital is a registered charity under the Income Tax Act (Canada) and accordingly is exempt from income taxes, provided certain requirements of the Income Tax Act are met.

The Hospital is funded primarily by the Province of Ontario in accordance with budget arrangements established by both the MOHLTC and the Toronto Central Local Health Integration Network (TCLHIN). During the fiscal year, the Hospital operated under two separate Hospital Service Accountability Agreements (HSAAs), from the predecessor hospitals, which set out the rights and obligations of the parties to the HSAAs in respect of funding provided to the Hospital by the MOHLTC/TCLHIN. These HSAAs set out the performance standards and obligations of the Hospital.

2. Summary of significant accounting policies

Basis of presentation

These financial statements have been prepared by management in accordance with Canadian public sector accounting standards (PSAS), including standards that apply to government not-for-profit organizations. A summary of the significant accounting policies is as follows:

Revenue recognition

The Hospital follows the deferral method of accounting for contributions, which includes donations and government grants. Unrestricted contributions are recognized as revenue when received or receivable. Externally restricted contributions are recognized as revenue in the year in which the related expenses are incurred.

Under the Health Insurance Act (Ontario) and the regulations thereunder, the Hospital is funded primarily by the Province of Ontario in accordance with funding arrangements established by the MOHLTC and TCLHIN.

Operating grants are recorded as revenue in the period to which they relate. Grants approved but not received at the end of a period are accrued. Where a portion of a grant relates to a future period, it is deferred and recognized in a subsequent period. These financial statements reflect management's best estimates of funding arrangements with the MOHLTC and TCLHIN.

All investment income is unrestricted and recognized as revenue when earned.

Amortization of building and research equipment is not included in the financial measures that are defined as part of the HSAA and accordingly has been reflected as an undernoted item in the statement of operations with the corresponding realization of revenue for deferred contributions and grants.

Contributions received in the form of donations and grants for specific capital expenditures are initially deferred and recorded as deferred capital contributions. These deferred contributions are realized into revenue on the same basis as the amortization of the cost of the related property and equipment. Funding for capital expenditures is recorded when there is an agreement with the ultimate donor and there is reasonable assurance the funding will be received in the near future.

Notes to the financial statements

March 31, 2016

(In thousands of dollars)

2. Summary of significant accounting policies (continued)

Revenue recognition (continued)

Revenue generated from patient, preferred accommodation, and commercial activities is recognized when the goods are sold or the service is provided, the amounts can be reasonably estimated and collection is reasonably assured.

Inventories

Inventories consist primarily of hospital supplies held for patient care and are recorded at the lower of cost and replacement cost. Cost is determined by the first-in, first-out method.

Property and equipment

Property and equipment are stated at cost, less accumulated amortization. Assets acquired under capital leases are amortized over the estimated life of the assets or over the lease term, as appropriate.

Contributed property and equipment are recorded at fair value at the date of contribution. When property and equipment no longer contribute to the Hospital's ability to provide services, their carrying amounts are written down to their residual value. Costs incurred for new facilities, or that substantially increase the useful lives of existing property and equipment, are capitalized.

Property and equipment are amortized on a straight-line basis over the estimated useful lives of the assets as follows:

Land	not amortized
Artwork	not amortized
Building	10 to 40 years
Equipment	3 to 20 years
Software	3 to 5 years
Equipment under capital lease	3 to 20 years
Construction-in-progress	not amortized

Construction-in-progress comprises direct construction, development costs and capitalized interest. Interest costs, net of related interest income, are capitalized during the construction period. No amortization is recorded until construction is substantially complete and the assets are put in use.

Contributed services

Certain ancillary services of the Hospital are voluntarily provided by the community. Since these services are not normally purchased by the Hospital and because of the difficulties in determining their fair value, these contributed services are not recognized in these financial statements.

Administered funds

Certain funds are administered by the Hospital on behalf of clinical groups. Transactions in the funds are not Hospital operating activities and do not flow through the statement of operations. Since these funds are held under administration, they are recorded as restricted cash on the statement of financial position with a corresponding liability.

Employee future benefit plans

a) Pension

Employees of the Hospital are eligible to be members of the Healthcare of Ontario Pension Plan (HOOPP or the Plan), which is a multi-employer, defined benefit pension plan. The Hospital has adopted defined contribution plan accounting for the Plan because insufficient information is available to apply defined benefit plan accounting.

Notes to the financial statements March 31, 2016 (In thousands of dollars)

2. Summary of significant accounting policies (continued)

Employee future benefit plans (continued)

b) Other than pension

Employees are also entitled to certain other non-pension, post-employment benefits. The Hospital accrues its obligations under non-pension employee benefit plans as employees render services and has adopted the following policies:

- The cost of non-pension post-employment benefits earned by employees is determined by an
 actuary using the projected benefit method pro-rated on length of service and management
 estimated assumptions with regard to retirement age of employees and expected healthcare
 costs.
- Past service costs arising from plan amendments are expensed when incurred.
- Actuarial gains and losses on the accrued benefit obligation arise from changes in the
 actuarial assumptions used to determine the accrued benefit obligations. The net accumulated
 actuarial gains or losses are amortized over the average remaining service period of active
 employees.

Use of estimates

The preparation of financial statements in conformity with PSAS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.

In addition, a portion of the revenue recognized from the MOHLTC and TCLHIN is an estimate. The Hospital entered into various accountability agreements with the TCLHIN that set out the rights and obligations of both parties in respect to funding provided to the Hospital by the TCLHIN and the MOHLTC. The accountability agreements set out certain performance standards and obligations that establish acceptable results for the Hospital's performance in a number of areas. If the Hospital does not meet its performance standards or obligations, the TCLHIN and/or the MOHLTC have the right to adjust funding received by the Hospital.

Other amounts which use estimates include capital assets, valuation of accounts receivable, valuation of certain accrued liabilities and obligations related to employee future benefits.

Related entities

Investments in Sinai Trust, Sinai Trust 2016 and Toronto Centre for Phenogenomics are accounted for using the modified equity method, whereby the investment is initially recorded at cost and adjusted thereafter to recognize the Hospital's share of the entity's net surplus or deficit. Any distributions received are accounted for as a reduction in the investment.

Interests in The Bridgepoint Collaboratory for Research and Innovation and Bridgepoint Health are disclosed.

Financial instruments

Financial instruments are recorded at fair value on initial recognition. Financial instruments, such as investments quoted in an active market and all derivative financial instruments are reported at fair value.

All other financial instruments, including fixed income investments, are recorded at amortized cost. Unrealized changes in fair value are recognized in the statement of remeasurement gains and losses until they are realized, when they are transferred to the statement of operations.

Notes to the financial statements

March 31, 2016

(In thousands of dollars)

2. Summary of significant accounting policies (continued)

Financial instruments (continued)

All financial assets are assessed for impairment on an annual basis. When a decline in value is determined to be other than temporary, the amount of the loss is reported in the statement of operations and any unrealized gain or loss is removed from the statement of remeasurement gains and losses.

When the asset is sold, the unrealized gains and losses previously recognized in the statement of remeasurement gains and losses are reversed and recognized in the statement of operations.

Long-term debt is recorded at cost. The related long-term forward interest rate swap is recorded at fair value.

PSAS requires the Hospital to classify fair value measurements using a fair value hierarchy, which includes three levels of information that may be used to measure fair value:

- Level 1 unadjusted quoted market prices in active markets;
- Level 2 observable or corroborated inputs, other than Level 1, such as quoted prices for similar assets or liabilities in inactive markets, or market data for substantially the full term of the assets or liabilities; and
- Level 3 unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.

The Hospital's investments are classified as Level 1. In management's opinion, the Hospital is not exposed to any significant credit, liquidity or market risk.

Foreign currency translation

Investments denominated in foreign currencies have been translated into Canadian dollars at exchange rates prevailing at the statement date. Investment income has been translated using exchange rates prevailing on the transaction date.

3. Cash

	2016	2015
	\$	\$
Operating funds	13,395	27,182
Restricted capital, research and designated funds	69,102	75,587
	82,497	102,769

Restricted capital, research and designated funds include externally restricted contributions received for specific purposes within the Hospital's operation.

Notes to the financial statements

March 31, 2016 (In thousands of dollars)

4. Restricted cash

	2016	2015
	\$	\$
Restricted cash held for redevelopment	1,062	461
Restricted funds under administration	10,799	10,603
Restricted cash - current	11,861	11,064
Restricted cash - long-term	4,272	9,473
Total restricted cash	16,133	20,537

- a) Under the terms of the Development Accountability Agreement with the MOHLTC, the Hospital has received funds from the MOHLTC related to the Bridgepoint redevelopment project that are restricted in use. The unspent portion of these funds as at March 31, 2016 is \$5,334 (2015 -\$9,934), which is held in a sinking fund trust account. The current portion of \$1,062 (2015 -\$461) relates to redevelopment obligations for fiscal 2017.
- b) Restricted funds under administration consist of cash held and administered by the Hospital on behalf of the clinical groups and cannot be used for Hospital operations.

5. Short-term investments

		2016		2015
	Cost	Fair value	Cost	Fair value
	\$	\$	\$	\$
Short-term investments in money market funds Short-term investments in Guaranteed	23,334	23,334	18,250	18,250
Investment Certificates (GICs)	-	-	2,500	2,500
	23,334	23,334	20,750	20,750

6. Accounts receivable

	2016	2015
	\$	\$
Research grants	9,061	11,030
MOHLTC	5,187	3,334
Commodity tax receivable	3,328	3,658
Patient services	5,056	4,710
Due from related entities (Note 14)	3,120	3,653
Other	14,677	11,701
	40,429	38,086

Patient accounts receivable are shown net of an allowance for potentially uncollectible amounts of \$818 (2015 - \$1,345).

Notes to the financial statements

March 31, 2016

(In thousands of dollars)

7. Capital grants receivable

Capital grants receivable relate to grants restricted in use to property and equipment acquisitions, which are receivable by the Hospital at year-end.

These amounts have also been included in deferred contributions related to property and equipment.

	2016	2015
	\$	\$
MOHLTC	3,617	3,617
Other	5,973	5,034
	9,590	8,651
Less: current portion	5,945	4,946
Long-term capital grants receivable	3,645	3,705

8. Other long-term assets

	2016	2015
	\$	\$
Healthcare Insurance Reciprocal of Canada (HIROC)		
deposits (Note 17(c))	3,710	2,940
Other (Note 14)	5,916	1,204
	9,626	4,144

9. Property and equipment

			2016	2015
		Accumulated	Net book	Net book
	Cost	amortization	value	value
	\$	\$	\$	\$
Land	7,166	-	7,166	7,166
Artwork	4,004	-	4,004	3,023
Building	1,235,840	293,868	941,972	961,673
Equipment	342,317	254,558	87,759	96,964
Equipment under capital lease	330	-	330	-
Software	6,691	5,654	1,037	1,095
Construction-in-progress	33,546	-	33,546	20,958
	1,629,894	554,080	1,075,814	1,090,879

Construction-in-progress consists primarily of surgical suites, critical care, emergency room and Lobby Mall renovations.

During the year, the Hospital acquired property and equipment of \$769 (2015 - \$4,266) financed by the long-term redevelopment obligation in Note 11, in relation to the BH redevelopment project under the terms of the Development Accountability Agreement with the MOHLTC.

In addition, the Hospital received donated assets of \$949 (2015 - \$3,023) and wrote off fully amortized assets of \$3,573 (2015 - \$34,763).

Notes to the financial statements

March 31, 2016

(In thousands of dollars)

9. Property and equipment (continued)

Renew Sinai redevelopment project

The Hospital, in conjunction with the MOHLTC, has undertaken a major multi-year capital redevelopment project to create, expand and modernize the Hospital space. Renew Sinai will enable the Hospital to leverage the best practices and advances in technology to deliver outstanding care to patients, and provide the best environment possible in which to work. As at March 31, 2016, the ongoing projects include the following:

a) Surgical suites, critical care, emergency room (MSH site)

In 2006, the Hospital began the preliminary planning and design of another phase of redevelopment involving the upgrade of the surgical suites, intensive care unit, medical and surgical inpatient units and the emergency room. The MOHLTC has approved a planning and design grant of \$37,500. As at

March 31, 2016, the costs incurred to date amounted to \$29,447 (2015 - \$13,151), which is 100% MOHLTC funded.

b) Lobby Mall renovation project (MSH site)

This project repurposes existing public space on the Hospital's main floor to create a welcoming lobby, enhanced food hall and a Welcome Centre for patients and families. Initial planning began in 2014. The project cost is \$18,000 with \$9,777 spent in 2016 (2015 - \$5,870). Completion is expected in May 2016. This project is funded entirely by the Sinai Health System Foundation (SHSF) and the community.

10. Long-term liabilities

	2016	2015
	\$	\$
Capital loans	38,980	39,799
General purpose loan	54,940	53,360
Long-term accrued sick days	4,707	4,618
Other long-term liability (Note 17(c))	3,074	2,511
Capital equipment financing	977	1,284
Obligation under capital lease	310	-
Fair value adjustment in respect of		
interest rate swap agreements	4,369	3,697
	107,357	105,269
Current portion of long-term liabilities	1,189	1,482
	106,168	103,787

a) The capital loans consist of two loans:

- An unsecured revolving term facility of \$10,000, repayable on April 15, 2017 and available by way of advances at the bank's prime rate, of which \$10,000 had been drawn as at March 31, 2016 (2015 \$10,000).
- ii) An unsecured non-revolving term facility of \$30,000, maturing on December 1, 2039, with a fixed interest rate of 3.85%, of which \$28,980 was drawn as at March 31, 2016 (2015 \$29,799).

Notes to the financial statements March 31, 2016 (In thousands of dollars)

10. Long-term liabilities (continued)

- b) A general purpose unsecured revolving credit facility of \$36,500, repayable in full on April 15, 2017, and available by way of advances at the bank's prime lending rate and bankers' acceptances.
 - In addition, the Hospital operates a cash management structure with its lender under which certain cash balances in the amount of \$29,028 (2015 \$32,465) are netted against the general purpose loan to assess credit limit availability and to calculate interest expense.
- c) In 2014, the Hospital entered into an agreement with a vendor to purchase capital equipment for the BH Site. The Hospital negotiated an interest free loan of \$1,727 effective March 30, 2014. The loan is repayable in five equal installments of \$345 each April 30, ending on April 30, 2018.
- d) In 2016, the Hospital entered into a capital lease agreement with a vendor for the MSH site. The total cost of the equipment is \$310 effective March 31, 2016. The lease is repayable in monthly installments of \$3 over a period of 98 months.
- e) The Hospital has entered into the following two interest rate swap contracts relating to its long-term debt, both of which are recorded at fair value. The fair value of the interest rate swap is based on current pricing for the same notional interest rate swap (Level 2 of the fair value hierarchy).
 - i) A notional principal amount of \$9,000 on the general loan (Note 10(b)) maturing on March 28, 2016. The interest rate swap is at a fixed interest rate of 5.68%. During the year, a gain of \$356 (2015 \$262) was recorded in the statement of remeasurement gains and losses. As at March 31, 2016, the swap has matured (2015 net unfavourable of \$356).
 - ii) A notional principal amount of \$30,000 (Note 10 (a)(ii)) maturing December 1, 2039. During the year, a loss of \$1,028 (2015 \$3,643) was recorded in the statement of remeasurement gains and losses. As at March 31, 2016, the swap was in a net unfavourable position and a liability of \$4,369 (2015 \$3,341) was recorded in long-term liabilities on the statement of financial position.
- f) An unsecured, revolving credit facility of \$10,000 to facilitate everyday operations; no funds have been drawn on the revolving line of credit.

Principal due within each of the next five years and thereafter on the capital loan, capital equipment and obligation of capital lease as at March 31, 2016 is as follows:

	•
2017	1,189
2018	11,233
2019	1,269
2020	963
2021	992
Thereafter	24,621
	40,267

\$

Notes to the financial statements March 31, 2016 (In thousands of dollars)

11. Long-term redevelopment obligation

In July 2009, the MOHLTC provided approval for BH to enter into a Project Agreement with the successful bidder for the construction of BH's Capital Redevelopment Project as a Design, Build, Finance and Maintain Alternative Financing and Procurement Project. The Project Agreement includes a 30-year facility maintenance period. The redeveloped BH Site is purpose built to serve those in need of rehabilitation services and those living with complex chronic disease.

The Hospital is committed to payments over 30 years for the capital and operating costs of the facility supported by the approval of the MOHLTC. The MOHLTC's share of the funding for the facility is supported by the Development Accountability Agreement. Annual funding from the MOHLTC is conditional on an appropriation of funds by the legislature of Ontario in the fiscal year in which the payment comes due.

The total project obligation within the Project Agreement is \$1,230,308. This obligation will be satisfied by MOHLTC funding of \$1,159,433 as per the Development Accountability Agreement. The balance of \$70,875 represents the local share obligation of the Hospital which, with the exception of \$10,578 in lifecycle payments due in future periods, was paid using a combination of restricted investments, foundation grants, and long-term bank debt. The obligations associated with the Project Agreement are recorded in these financial statements in today's dollars.

	2016	2015
	\$	\$
Long-term redevelopment obligation, due Feb. 28, 2043 monthly payments of \$2,112 including principal		
and interest at 7.46%	375,181	380,827
Current portion	6,743	6,415
	368,438	374,412

Principal due within each of the next five years and thereafter, on the long-term redevelopment obligation to be fully funded by the MOHLTC, is as follows:

	\$
2017	6,743
2018	7,088
2019	7,451
2020	7,832
2021	8,232
Thereafter	337,835
	375,181

Notes to the financial statements March 31, 2016

(In thousands of dollars)

12. Employee future benefits

Pension plan

Substantially all employees are eligible to be members of HOOPP, which is a multi-employer defined benefit pension plan. Plan members will receive benefits based on length of service and on the average of annualized earnings during the five consecutive years prior to retirement, termination, or death, which provide the highest earnings.

The most recent actuarial valuation of the Plan as at December 31, 2015 indicates the Plan is 122% funded. During the year, the Hospital contributed \$26,070 (2015 - \$25,674) to the Plan on behalf of employees.

Other post-employment benefits

The Hospital provides extended healthcare, dental and life benefits to certain of its employees and extends this coverage to the post-retirement period. In addition, a Supplemental Executive Retirement Plan (SERP) is available for a limited number of executive members. The related benefit liabilities were determined by actuarial valuation studies. The dates of the last actuarial valuation for MSH and BH were March 31, 2016.

The employee future benefits as at March 31 include the following components:

			2016	2015
		Post-		
	е	mployment		
	SERP	benefits	Total	Total
	\$	\$	\$	\$
Accrued benefit obligation	7,999	24,242	32,241	30,848
Unamortized actuarial losses	(816)	(4,461)	(5,277)	(5,814)
Employee future benefits liability recorded				
in the statement of financial position	7,183	19,781	26,964	25,034
Less: current portion	376	678	1,054	500
Long-term portion	6,807	19,103	25,910	24,534

The movement in the employee future benefits liability during the year is as follows:

			2016	2015
		Post-		
		employment		
	SERP	benefits	Total	Total
	\$	\$	\$	\$
Employee future benefits liability - April 1, 2015	7,047	17,987	25,034	23,559
Current service cost	57	1,149	1,206	970
Interest cost	318	727	1,045	1,102
Amortization of actuarial losses	142	263	405	174
Pension and post-employment benefits expense	517	2,139	2,656	2,246
Benefits paid	(381)	(345)	(726)	(771)
Employee future benefits liability - March 31, 2016	7,183	19,781	26,964	25,034

Notes to the financial statements March 31, 2016 (In thousands of dollars)

12. Employee future benefits (continued)

The significant actuarial assumptions adopted in measuring the Hospital's accrued benefit obligations are as follows:

		2016		2015
		Post-		Post-
		employment		employment
	SERP	benefits	SERP	benefits
	%	%	%	%
Discount rate	3.25	3.25	3.50	3.00 - 3.25
Expected benefit cost trend in health care *	-	6.25	-	7.25 - 8.00
Expected benefit cost trend in dental care	-	3.00	-	4.00

The average remaining service period of active employees is 14 to 15 years (2015 - 14 to 16 years).

13. Deferred contributions

					2016	2015
	Capital	Designated	Research	Other		
	funds	funds	funds	operating	Total	Total
	\$	\$	\$	\$	\$	\$
Balance - Beginning of the year	615,218	13,548	47,685	197	676,648	673,183
Contributions received	31,929	9,399	70,519	-	111,847	130,078
Amortization/recognition	(48,458)	(9,645)	(66, 282)	-	(124,385)	(126,613)
Balance - End of the year	598,689	13,302	51,922	197	664,110	676,648
Less: current portion	4,941	13,302	51,922	-	70,165	76,048
Long-term portion	593,748	_	-	197	593,945	600,600
		-	,	197		

The current portion of deferred contributions represents the unspent amount of externally restricted contributions received for specific purposes. The long-term portion of deferred contributions represents the unamortized amount of contributions, which has been used for the purchase of property and equipment.

14. Related entities

The Bridgepoint Collaboratory for Research and Innovation (The BCRI)

The BCRI is a non-share capital corporation incorporated pursuant to the laws of Canada. The BCRI continued under the Canada Not-for-profit Corporations Act and is a registered charity (charitable organization) under the Income Tax Act (Canada). It conducts clinical research supporting the care of clients served by the BH site of the Hospital. The members of The BCRI are the directors of the Hospital. The BCRI has not been consolidated in the Hospital's financial statements. During the year, BH provided grants in the amount of \$61 (2015 - \$79).

^{*} The rate is presumed to decline by 0.25 percentage points per annum to an ultimate rate of 4.50%.

Notes to the financial statements March 31, 2016 (In thousands of dollars)

14. Related entities (continued)

Bridgepoint Foundation (BF)

BF is a non-share capital corporation incorporated pursuant to the laws of the Province of Ontario. BF is a registered charity (public foundation) under the Income Tax Act (Canada). The Hospital and BF share an executive and have a limited number of common directors. BF supports the Hospital in its charitable mission and BF grants funds to the Hospital as approved by the Board of Directors of BF. During the year, BF provided operating grants in the amount of \$56 (2015 - \$404) and capital grants in the amount of \$835 (2015 - \$291).

Bridgepoint Health (Health)

Health is a non-share capital corporation incorporated pursuant to the laws of Canada. Health continued under the Canada Not-for-profit Corporations Act and is a registered charity (private foundation) under the Income Tax Act (Canada). Health generates ancillary revenue to support the activities of the Hospital and The BCRI.

Effective January 1, 2015, the members of Health are the directors of the Hospital. Health has not been consolidated in the Hospital's financial statements.

The Hospital provides space and administrative services to Health. During the year, Health granted \$550 (2015 - \$170) to the Hospital for the purpose of funding the redevelopment project. The Hospital has credit facilities arranged related to its capital redevelopment project. Health has provided a guarantee to the Hospital's credit facilities for its capital redevelopment project. As at March 31, 2016, there were no significant restrictions on the resources of Health and the accounting policies followed by Health substantially conform with those of the Hospital. A financial summary of this non-consolidated entity as at March 31, 2016 is as follows:

2016	2015		2016	2015
\$	\$		\$	\$
		Results of operations		
5,816	5,685	Total revenue	1,171	968
279	249	Total expenses	(1,070)	(887)
5,537	5,436	Excess of revenue	101	81
		over expenses		
	\$ 5,816 279	\$ \$ 5,816 5,685 279 249	\$ \$ Results of operations 5,816	\$ \$ Results of operations 5,816 5,685 Total revenue 1,171 279 249 Total expenses (1,070) 5,537 5,436 Excess of revenue 101

There were cash outflows of \$32 (2015 - \$141) from operating activities, \$18 (2015 - \$331) from capital activities and \$4 (2015 - \$nil) from financing activities.

The Hospital provides banking services to Health, The BCRI and BF. The Hospital makes payments and receives funds on behalf of these entities, and settles the outstanding balances at regular intervals throughout the year. No financing charges are levied on these interim balances. As at March 31, 2016, Health owed the Hospital \$232 (2015 - \$167), The BCRI owed the Hospital \$6 (2015 - \$59), and the Hospital owed BF \$4 (2015 – BF owed the Hospital \$306). These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related entities.

Circle of Care (CoC)

On October 28, 2014, the TCLHIN approved the voluntary affiliation of the Hospital with CoC, a community based not-for-profit agency whose objectives include providing home care services to individuals across Metropolitan Toronto. CoC is a separate corporation with its own Board of Directors. The Hospital's Board of Directors is responsible for appointing 50% of the CoC Board of Directors. CoC is a registered charity (charitable organization) under the Income Tax Act (Canada). There were no material transactions between the Hospital and the CoC for the year ended March 31, 2016.

Notes to the financial statements March 31, 2016 (In thousands of dollars)

14. Related entities (continued)

Sinai Health System Foundation of Toronto (SHSF)

SHSF is a non-share capital corporation incorporated pursuant to the laws of the Province of Ontario. SHSF is a charitable organization (public foundation) registered under the Income Tax Act (Canada). The Hospital and SHSF share an executive and have a limited number of common directors.

SHSF supports the Hospital in its charitable mission and provides donations to the Hospital for capital, clinical programs and research activities of the Lunenfeld-Tanenbaum Research Institute (LTRI), a division of the Hospital. During the current year, the Hospital received \$30,676 (2015 - \$35,063) in donations from SHSF. In addition, SHSF has contributed funding for a portion of the current year's bank interest expense in the amount of \$33 (2015 - \$58).

The total amount receivable from SHSF as at March 31, 2016 is \$6,085 (2015 - \$6,909), of which an estimated amount of \$1,314 (2015 - \$2,113) will be received within one year and is included in accounts receivable. The remaining balance of \$4,771 (2015 - \$4,796) is accordingly classified as a long-term receivable.

The Sinai Trust (Trust)

The Trust, a for-profit entity, established to develop commercial opportunities for the benefit of the Hospital and SHSF, has a December 31 year-end. Sinai Trustee Corporation (Trustee), a non-share capital corporation incorporated pursuant to the laws of Canada, serves as the trustee of the Trust.

The Hospital accounts for its interest in the Trust based on the modified equity method. The Hospital recorded an operating profit of \$nil (2015 - \$3) in the statement of operations and the investment is recorded in prepaid deposits and sundry assets.

The Sinai Trust 2016 (Trust 2016)

Trust 2016, a for-profit entity, was established on March 31, 2016 to develop commercial opportunities for the benefit of the Hospital and the SHSF. Trustee, a non-share capital corporation incorporated pursuant to the laws of Canada, serves as the trustee of Trust 2016.

The Hospital accounts for its interest in Trust 2016 based on the modified equity method. The Hospital recorded an operating profit of \$nil in the statement of operations and \$4,000 promissory note in other long-term assets.

Toronto Centre for Phenogenomics (TCP)

TCP is an unincorporated joint venture between the Hospital and the Hospital for Sick Children, comprising a 120,000 square foot of state-of-the-art mouse research facility. On May 11, 2004, TCP entered into a lease with the Hospital to rent space in the research building for a term of 30 years at a basic rent of \$10 per annum. The lease commenced on June 27, 2007.

The Hospital's interest in TCP is 50%. The Hospital uses the modified equity method to record its share of TCP's operating loss of \$nil (2015 - \$nil) in the statement of operations and the investment is recorded in prepaid deposits and sundry assets.

During the year, the Hospital provided support services to TCP, on a cost recovery basis, amounting to \$419 (2015 - \$425) and TCP provided research facilities and services to LTRI, on a cost recovery basis, amounting to \$559 (2015 - \$533).

As at March 31, 2016, the Hospital has a net receivable from TCP amounting to \$180 (2015 - net payable of \$213), which has been included in accounts receivable.

Notes to the financial statements

March 31, 2016

(In thousands of dollars)

15. Lunenfeld-Tanenbaum Research Institute (LTRI)

The Hospital carries on its research mission through LTRI, a division of the Hospital. The purpose of the research is to improve health outcomes. Funding for LTRI is provided by a variety of external sources, including governments, charitable organizations, private industry, and SHSF.

16. Statements of cash flows

The net change in non-cash working capital balance relating to operations consists of the following:

	2016	2015
	\$	\$
Accounts receivable	(2,343)	4,459
Inventories	99	241
Prepaid deposits and sundry assets	(764)	167
Accounts payable and accrued liabilities	(7,644)	(11,798)
	(10,652)	(6,931)

17. Commitments and contingencies

- a) From time to time, the Hospital is named in lawsuits related to its activities. These claims are at various stages and therefore it is not possible to determine the merits of these claims or to estimate the possible financial liability, if any, to the Hospital. Accordingly, no material provisions have been made for loss in these financial statements.
- b) Future operating commitments related to future lifecycle costs (for the BH site), leases, and contracts for facility operating and maintenance as at March 31, 2016 are as follows:

2017	10,607
2018	9,891
2019	10,531
2020	10,477
2021	8,394
Thereafter	164,578
	214,478

c) The Hospital is a member of HIROC and therefore has an economic interest in HIROC. HIROC is a pooling of the public liability insurance risks of its members which are Canadian not-for-profit healthcare organizations. All members of HIROC pay annual premiums, which are actuarially determined. All members are subject to assessment for losses, if any, experienced by the pool for the years in which they were members. No assessment has been made for the year ended March 31, 2016.

Since its inception in 1987, HIROC has accumulated an unappropriated surplus, which is the total of premiums paid by all subscribers plus investment income, less the obligation for claims reserves and expenses and operating expenses.

\$

Notes to the financial statements March 31, 2016 (In thousands of dollars)

17. Commitments and contingencies (continued)

In 2012, the Hospital entered into an agreement with HIROC whereby HIROC continues to provide indemnity insurance to the Hospital; however, the cost of investigating and defending any litigation claims, previously included in the insurance premium, will be borne by the Hospital.

Under the agreement, the Hospital provides deposits to HIROC Management Limited (HML), which acts as an agent to pay legal expenses on behalf of the Hospital. For the year ended March 31, 2016, the Hospital has recorded legal expenses of \$1,192 (2015 - \$1,138) based on the assessment of the actuary engaged by HML, which have been included in the statement of operations. As at March 31, 2016, the deposit balance was \$4,330 (2015 - \$3,453), of which \$3,710 (2015 - \$2,940) is not expected to be used within one year and is therefore disclosed as a long-term asset (Note 8), and the total liability was estimated to be \$3,693 (2015 - \$3,023), of which \$3,074 (2015 - \$2,511) is not expected to be paid within one year and is therefore disclosed as a long-term liability (Note 10).

- d) Effective March 31, 2006, the Hospital entered into an agreement with Plexxus, whose primary responsibility is to provide supply chain services in the areas of strategic sourcing, logistics, buying and certain information technology services. The objective is to provide these services at a lower cost as compared to the members' costs prior to entering into the agreement. Based on the agreement, Plexxus has the right to charge membership fees to its members. A process is established in the agreement for Plexxus to obtain the approval of the members to charge additional fees. If any member fails to pay their membership fees to Plexxus throughout the period covered by the agreement, the Hospital and the other members are responsible for lending an amount to Plexxus, based on a sharing formula, to cover these deficiencies. As at March 31, 2016, no member was in default.
- e) The Hospital has entered into various contracts for construction and purchase of capital equipment. The commitments outstanding as at March 31, 2016 are estimated to be \$10,323 (2015 \$25,852).

18. Financial instruments and risk management

Financial instruments

The Hospital's financial instruments are generally classified and measured as follows:

Assets/liabilities	Measurement category		
Cash and cash equivalents	Fair value		
Short-term investments	Fair value		
Account receivable	Amortized cost		
Capital grants receivable	Amortized cost		
Due from related party	Amortized cost		
Accounts payable and accrued liabilities	Amortized cost		
Short-term financing	Amortized cost		
Long-term liabilities	Amortized cost		
Interest rate swaps	Fair value		

All financial assets, except the interest rate swaps, are tested annually for impairment. When financial assets are impaired, impairment losses are recorded in the statement of operations.

For financial instruments measured using amortized cost, the effective interest rate method is used to determine interest income or expense.

Notes to the financial statements

March 31, 2016

(In thousands of dollars)

19. Financial instruments and risk management (continued)

Derivatives

The Hospital currently employs interest rate swaps to convert the variable interest rate on \$30,000 (Note 10(e)) of its bank loans to a fixed interest rate. The interest rate swaps are employed in order to eliminate variability in future interest cash flows. The swaps are measured at fair value until settled. The change in fair value of the swap is recorded in the statement of remeasurement gains and losses.

Risk management

The Hospital is exposed to a variety of financial risks, including credit risk, liquidity risk and market risk. The Hospital has adopted an integrated risk management framework. The framework provides a consistent methodology to manage risks across the Hospital.

Credit risk

As at March 31, 2016, the Hospital's exposure to credit risk in the event of non-payment by patients for non-insured services and for services provided to non-resident patients is not material.

Liquidity risk

Liquidity risk is the possible risk of not being able to meet financial obligations when due. The Hospital manages its liquidity risk by forecasting cash flows from operations and anticipating capital, investing and financing activities and maintaining credit facilities to ensure it has sufficient funds available to meet current and foreseeable financial requirements.

The table below is a maturity analysis of the Hospital's financial liabilities as at March 31, 2016:

		More than			
		6 months	More than		
	Up to 6	up to 1	1 year up	More than	
	months	year	to 5 years	5 years	Total
	\$	\$	\$	\$	\$
Accounts payable and					
accrued liabilities	77,271	7,247	-	-	84,518
Long-term liabilities	-	1,188	72,472	33,697	107,357
	77,271	8,435	72,472	33,697	191,875

Market risk

The Hospital is exposed to market risk through the fluctuation of financial instrument fair values due to changes in market prices. Interest rate risk is the significant market risk, which arises from fluctuations in interest rates and the degree of volatility of those rates. The Hospital is exposed to interest rate risk on its long-term debt (Note 10). The Hospital has mitigated this risk by way of interest rate swaps, which effectively fix the interest rates of a portion of the long-term debt, and utilizes mirror netting with a significant portion of the cash balance, which effectively reduces the interest on the floating rate portion of the debt.

As at March 31, 2016, the Hospital's estimate of the exposure to interest rate risk and the effect on net assets is not material.

20. Subsequent event

Subsequent to year end, the Hospital issued \$200,000 in debentures related to the financing of its capital redevelopment projects.